全文获取类型
收费全文 | 221篇 |
免费 | 8篇 |
专业分类
儿科学 | 1篇 |
基础医学 | 10篇 |
临床医学 | 10篇 |
内科学 | 20篇 |
皮肤病学 | 1篇 |
神经病学 | 19篇 |
特种医学 | 1篇 |
外科学 | 11篇 |
综合类 | 41篇 |
药学 | 54篇 |
肿瘤学 | 61篇 |
出版年
2024年 | 1篇 |
2023年 | 1篇 |
2022年 | 4篇 |
2021年 | 2篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 4篇 |
2014年 | 9篇 |
2013年 | 7篇 |
2012年 | 8篇 |
2011年 | 8篇 |
2010年 | 9篇 |
2009年 | 8篇 |
2008年 | 9篇 |
2007年 | 8篇 |
2006年 | 12篇 |
2005年 | 9篇 |
2004年 | 19篇 |
2003年 | 5篇 |
2002年 | 7篇 |
2001年 | 12篇 |
2000年 | 9篇 |
1999年 | 4篇 |
1998年 | 7篇 |
1997年 | 10篇 |
1996年 | 7篇 |
1995年 | 10篇 |
1994年 | 7篇 |
1993年 | 4篇 |
1992年 | 7篇 |
1991年 | 1篇 |
1990年 | 5篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 1篇 |
排序方式: 共有229条查询结果,搜索用时 15 毫秒
1.
P. Cavalla V. Rovei S. Masera M. Vercellino M. Massobrio R. Mutani A. Revelli 《Neurological sciences》2006,27(4):231-239
Abstract The issue of fertility in patients with multiple sclerosis (MS) has not been exhaustively studied. Epidemiological data have
suggested that spontaneous fecundity might be reduced; several endocrine and sexual disturbances potentially interfering with
reproduction have been evidenced in MS patients of both sexes. Moreover, some medical treatments used in MS (e. g., mitoxantrone,
cyclophosphamide) may exert detrimental effects on spermatozoa as well as on oocytes, leading to early impairment of fertility.
This review illustrates the factors potentially interfering with fertility in MS and discusses the therapeutic tools that
may be used to promote fertility in these patients. The safety of hormonal therapies in MS is also examined. The current applications
of assisted reproductive technology (ART) are discussed, including in vitro fertilisation (IVF) techniques. Currently available methods to preserve fertility in patients that undergo cytotoxic treatments
by means of sperm/oocyte cryostorage or by ovarian fragment cryopreservation and autografting are considered. 相似文献
2.
目的:为评估由三苯氧胺、环磷酰胺、氨甲喋呤和顺铂组成的TCMP方案对常规化疗耐药后复发转移性乳腺癌的疗效.方法:25例对常规化疗耐药的复发转移性乳腺癌患者接受TCMP方案化疗.给药方法是三苯氧胺,10mg,口服,每天2次;环磷酸胺,0.8~1.0,静推,第1天;氨甲喋呤,40mg,肌注,第1、8天;顺铂40mm,静滴,第1~4天.23例患者有客观评价指标,均接受TCMP方案化疗最小2周期.结果:23例可评价患者中,总客观有效率为52.17%(95%可信区间31~73%),其中2例CR,10例PR.经Ridit检验治疗效果与雌激素受体状态无关.结论:以上提示TCMP方案对常规治疗耐药后复发转移性乳腺癌有较好疗效,三苯氧胺与以顺铂为主化疗方案在乳腺癌的治疗中有协同作用. 相似文献
3.
4.
目的 观察总结米托蒽醌(MTZ)联合治疗儿童难治性复发性急性白血病(RRAL)的疗效。方法 RRAL 12例,急性淋巴细胞白血病(ALL)9例,急性髓性白血病(AML)3例;ALL用VMLP/Dex方案(长春新碱、米托蒽醌、左旋门冬酰胺酶、泼尼松/地塞米松)2~4周;AML用MAE方案(米托蒽醌、阿糖胞苷、依托泊苷)或大剂量阿糖胞苷+依托泊苷。结果 9例ALL,CR 7例,PR 1例,1例未复查;3例AML,CR 2例,NR 1例。总CR率为81.8 %(9/11),总有效率90.9 %(10/11)。用药后骨髓抑制较明显,大部分病例ANE≤0.1×109/L持续1~2周,轻微肝功能损害,未见药物相关的心脏损害。结论 MTZ不失为治疗儿童难治性复发性急性白血病的有效药物之一,用药后要注意预防和治疗骨髓抑制后出现的各种感染和出血。 相似文献
5.
Janke Greidanus Pax H. B. Willemse Donald R. A. Uges Evrard T. H. G. J. Oremus Zacharias J. Langen Elisabeth G. E. Vries 《Pharmacy World & Science》1988,10(6):237-245
With the recent development of reliable portable pumps and safe venous access systems, continuous infusion of chemotherapeutic agents on an out-patient basis has become feasible. Advantages of continuous infusion are the long-term exposure of tumour cells to the drug and the fact that most toxic effects are reduced for doxorubicin, epirubicin and mitoxantrone due to elimination of the high peak plasma levels. Preliminary data for doxorubicin suggest that its antitumour activity is maintained. Pharmacokinetic studies with epirubicin and mitoxantrone showed a linear relationship between drug dose infused and the steady-state plasma level for these drugs. The area under the curve for leukocytes drug level was higher during continuous infusion than after an equitoxic bolus injection of epirubicin and mitoxantrone. Well-randomized clinical trials will be necessary to investigate the role of continuous infusion of antracyclines and mitoxantrone in cancer chemotherapy in the future. 相似文献
6.
7.
Thomas X Elhamri M Chelghoum Y Reman O Arnaud P Raffoux E Le QH Tavernier E Dombret H Michallet M 《Annals of hematology》2005,84(6):376-382
Following a dose-escalation study performed to assess the maximally tolerated dose of high-dose mitoxantrone in a single injection combined with chemotherapy, a phase II trial (EMA 2000 regimen) was performed in patients with refractory or relapsed acute myelogenous leukemia (AML) between October 2000 and December 2003. Sixty-two patients entered the study and received mitoxantrone 45 mg/m2 on day 1 in combination with cytarabine and etoposide. Overall, 39 patients (63%) achieved complete remission (CR). Four patients died during remission induction, and 19 patients had resistant disease. Median time to granulocyte and platelet recovery was 34 and 39 days, respectively. The predominant non-hematologic toxicity was infection, with 53% severe infections. Thirty-three of the 39 remitters received subsequent treatment consisting of maintenance chemotherapy courses in 17 patients, allogeneic stem cell transplantation (SCT) in 7 patients, and autologous SCT in 9 patients. The median overall survival of the entire cohort was 8.1 months, with 18% at 2.5 years. EMA chemotherapy using a single injection of mitoxantrone is effective in the treatment of high-risk AML. CR proportion was significantly higher in patients with a first CR duration 6 months when compared with those from a control trial using standard-dose mitoxantrone (90 vs 70%, p=0.03). 相似文献
8.
应用国产盐酸米托蒽醌注射液单药和组成联合化疗方案治疗各类恶性肿瘤230例,在可评定疗效的218例中,白血病单药有效率43.8%,联合化疗有效率81.8%;恶性淋巴瘤单药有效率61%,联合化疗有效率65.5%;乳腺癌单药有效率34.6%,联合化疗有效率50%。主要毒副作用是白细胞减少,未见严重的心脏毒性。我们认为米托蒽醌是一有效的、值得临床推广应用的抗肿瘤药。 相似文献
9.
【摘要】目的 探讨中剂量阿糖胞苷联合米托蒽醌及依托泊甙巩固治疗对难治复发性急性髓系白血病(AML)患儿的疗效及安全性。方法 选取2008年12月~2012年12月我院收治的行阿糖胞苷联合米托蒽醌、依托泊甙巩固治疗的难治复发性AML患儿96例作为研究对象,采用回顾性分析法分析所有患儿的临床及随访资料,根据阿糖胞苷使用剂量的不同将其分为低剂量组、中剂量组和高剂量组3组,每组各32例,治疗结束后分析并比较3组患儿近期和远期临床疗效,并记录3组患儿治疗过程中不良反应的发生情况。结果 近期临床总有效率3组相比较差异均无统计学意义(P>0.05),且所有部分缓解的患儿中8例患儿进行骨髓移植治疗后治愈,余42例继续采用药物进行治疗;3组患儿5年总生存率(OS)比较差异有统计学意义(P>0.05),中剂量组和高剂量组患儿5年OS均高于低剂量组(P>0.05),但中剂量和高剂量组5年OS比较差异无统计学意义(P>0.05),3组患儿其5年无事件生存年率(EFS)比较差异均无统计学意义(P>0.05);3组患儿在骨髓抑制和心脏毒性的不良反应方面比较差异无统计学意义(P>0.05),但中剂量组和高剂量组患儿其感染、胃肠道反应以及肝肾功能损伤的不良反应发生率均显著高于低剂量组,且高剂量组患儿胃肠道和肝肾功能损伤的不良反应发生率均高于中剂量组患儿,组间比较差异均有统计学意(P>0.05)。结论 中剂量阿糖胞苷联合米托蒽醌及依托泊甙巩固治疗对难治复发性AML患儿具有较好的临床疗效和较低的毒副反应,存在一定的安全性,可作为临床上治疗AML患儿的首选治疗方案。 相似文献
10.
Mitoxantrone is a member of the anthracendione family developed to treat malignancies and increasingly used to treat multiple sclerosis (MS). It has been studied as a treatment for MS since the late 1980s, and is licensed in a number of countries for progressive and worsening MS. Review of the published earlier open-label, and more recently of controlled trials suggests that mitoxantrone is efficacious in cases of worsening MS that have an inflammatory component as evidenced by progression with or without superimposed relapses and/or gadolinium (Gd) enhancing magnetic resonance (MR) lesions. Today there is no robust evidence of efficacy in primary progressive MS or in later stages of secondary progressive MS beyond an EDSS score of 6. Relevant immunomodulatory mechanisms act both on T- and B-cell function, and mitoxantrone has selective immune effects in MS by decreasing levels of TNF-alpha, IL-2, IL-2R-beta1, IL-10 and IFN-gamma. Adverse events include nausea, alopecia, infections, menstrual disorders, risk of cardiotoxicity and malignancy. Different regimens are used according to different regulatory demands in different countries. The two most commonly used regimens are every 3 months intravenous (i.v.) 12 mg/m2 for 2 years or 20 mg mitoxantrone (i.v.) combined with 1 g methylprednisolone (i.v.) every 4 weeks for 6 months. The cumulative life dose in MS patients is 140 mg/m2. Mitoxantrone is currently used as a second line drug in MS patients whose disease is not controlled by beta-interferon or glatiramer acetate. In this review, we will discuss the clinical disease patterns of MS patients who are most likely to benefit from mitoxantrone, its magnitude of clinical effect, and limitations of using mitoxantrone in MS. Mitoxantrone as a second line therapy in non-responders of beta-interferon and glatiramer acetate will be assessed. Recent strategies of combination therapy, and the optimal dose regimen will also be discussed. 相似文献